Skip to main content

Table 3 Steady-state plasma pharmacokinetics of SBECD and voriconazole during CVVH

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

SBECD

       
 

Cmax (mg/L)

Cmin (mg/L)

T1/2 (hrs)

AUC0-12 (mg*hr/L)

Cls(L/hr/kg)

Vd (L/kg)

CVVH CL (L/hr/kg)

Mean

687.0

214.5

6.3

4396

0.03

0.3

0.02

SD

500.4

202.6

1.6

3325

0.02

0.2

0.01

Median

561.1

165.2

6.2

3621

0.02

0.2

0.01

25%

216.2

38.7

5.3

1352

0.01

0.1

0.01

75%

1102.4

305.8

7.3

6804

0.05

0.4

0.02

Voriconazole

       
 

Cmax (mg/L)

Cmin (mg/L)

T1/2 (hrs)

AUC0-12 (mg*hr/L)

Cls(L/hr/kg)

Vd (L/kg)

CVVH CL (L/hr/kg)

Mean

4.1

2.4

19.5

37

0.13

3.2

0.02

SD

1.4

1.1

10.7

14

0.06

1.5

0.02

Median

4.1

2.3

19.0

38

0.12

2.7

0.02

25%

3.3

2.0

13.1

30

0.09

2.1

0.01

75%

5.1

3.0

22.5

41

0.14

3.7

0.02

  1. SBECD, sulfobutylether-β-cyclodextrin; CVVH, continuous venovenous hemofiltration; Cmax, maximum drug concentration in the plasma; Cmin, minimum drug concentration in the plasma; T1/2, half-life; AUC0-12 area under the concentration-time curve from time 0 to 12 hours; Cls, total systemic clearance; Vd, volume of distribution; CVVH CL clearance by continuous venovenous hemofiltration; SD, standard deviation.